In January, Deutsche Bank's global forex strategist, George Saravelos roused the ire of Bessent by suggesting Europeans might sell their holdings of U.S. Treasurys after Trump imposed punitive tariffs ...

SoftBank recorded a $4.2 billion gain on its investment in OpenAI last quarter. SoftBank, the Japanese tech investor that is ...

Yili is the largest dairy producer in China, having overtaken Mengniu in revenue and market share in the early 2010s. It has strategically targeted the ultra-high-temperature milk and yogurt segments, ...

Dow Jones Top Energy Headlines at 4 AM ET: Oil Rises on U.S.-Iran Tensions Despite Crude Build | Origin ... Oil prices rose in early trading on U.S.-Iran tensions, despite the build-up of U.S. crude ...

While tech-powered eyewear spurred EssilorLuxottica's top line last year, it weighed on the group's profitability. The adjusted operating margin slipped to 16.0% in 2025 from 16.7% a year earlier as ...

"As global refinery activity declines seasonally from an all-time high reached in December, and oil supply recovers from recent outages, it remains to be seen when surplus barrels finally move ashore ...

Shares of Adyen, one of Europe's few high-growth tech stocks, slumped on Wednesday after outlining revenue growth that disappointed investors and forecasting steady margins.

In Europe, the Stoxx Europe 600 gained 0.6% in morning trading. Schroders rose 29% and Embracer Group Series B rose 12.9%. On the other hand, Adyen lost 20.4%, and DSM-Firmenich sunk 9.1%. The FTSE ...

Hong Kong-listed Meituan's shares fell to their lowest intraday level since March 2024 on Thursday after Moody's Ratings revised the food-delivery platform's ratings outlook to negative. The stock ...

Chicago-based Nuveen said Thursday it had agreed to buy the U.K's Schroders (UK:SDR), a 222-year-old London-headquartered asset manager for up to 612 pence per share, valuing the company at ...

Samsung Electronics has begun shipments of the most advanced high-bandwidth memory products, known as HBM4.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company makes lump-sum payments in exchange for future ...